Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

82
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
82
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

149
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
149
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

92
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
92
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

111
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
111
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

126
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
126

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Time-dependent pattern of liver injury biomarkers in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.

European journal of pediatrics·2026
Same author

Neonatal PBPK model of midazolam and its metabolites for perinatal asphyxia and therapeutic hypothermia.

British journal of clinical pharmacology·2026
Same author

Physiologically Based Pharmacokinetic Modelling of Hydroxyurea in Patients with Sickle Cell Disease: A Special Focus on Lactating Women and Breastfed Infants to Inform Safe Dosing and Breastfeeding Strategies.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population pharmacokinetic modelling of amoxicillin in human breast milk-A contribution from the ConcePTION project.

British journal of clinical pharmacology·2026
Same author

Electronic Patient File-Embedded Model-Informed Precision Dosing Compared with Physician Dosing of Tacrolimus in Kidney Transplantation.

Clinical pharmacology and therapeutics·2025

相关实验视频

Updated: Sep 12, 2025

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.5K

预测系统性和肝脏博森坦暴露使用生理学基础的药理动力学建模.

Miao-Chan Huang1, Julia Macente1, Sofie Heylen1

  • 1Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.

CPT: pharmacometrics & systems pharmacology
|August 5, 2025
PubMed
概括

一种新的生理学基础的药理动力学 (PBPK) 模型预测肝脏暴露于博森坦,有助于评估肺动脉高血压患者的风险. 这种模型有助于弥合体外和体内数据,以更好地了解波森坦诱导的肝损伤.

关键词:
这是一个OATP1B1B1的OATP.这是一个OATP1B3B3的OATP.自动诱导是一种自动诱导.博斯坦坦 bosentan 博斯坦坦 bosentan 博斯坦坦肝脏药物暴露 肝脏药物暴露暴露于肝脏的情况.建模和模拟的模型和模拟.基于生理学的药理动力学 (PBPK) 模型.未结合的肝脏度与未结合的血度的比率.

更多相关视频

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

相关实验视频

Last Updated: Sep 12, 2025

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
07:23

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications

Published on: October 20, 2023

1.5K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 毒理学 毒理学 毒理学
  • 生物医学工程 生物医学工程

背景情况:

  • 博森坦是一种用于肺动脉高血压 (PAH) 的口服药物,具有肝损伤风险的黑盒警告.
  • 了解博森坦的肝损伤机制对于准确的风险评估至关重要.
  • 将机械学数据与肝脏森坦度相结合,可以提高风险评估.

研究的目的:

  • 开发一种基于生理学的药理动力学 (PBPK) 模型,以预测博森坦的肝部位和肝内暴露.
  • 为了使森坦诱导的肝损伤的风险评估更加动态和相关.

主要方法:

  • 设计了PBPK模型开发的工作流程,重点关注博森坦的肝部位.
  • 利用临床血和分泌数据来完善肝脏清除量的估计.
  • 与观察到的系统和排泄数据对比验证的模型预测.

主要成果:

  • 该PBPK模型准确地预测了博森坦的全身循环和分泌.
  • 模型衍生的内在肝清除与临床研究结果一致.
  • 模拟的稳定状态未结合的肝脏森坦暴露在1.65至34.1 ng/mL之间.
  • 模拟未结合的肝脏与血度的比率在0.80和2.93.9之间变化.

结论:

  • 成功开发了一种博森坦PBPK模型,准确预测肝脏的处置.
  • 该模型可以预测肝脏的博森坦暴露,将体外毒理学发现与体内效应联系起来.
  • 该工具有助于更全面地评估森坦诱导的肝损伤的风险.